Reimagining human-centric drug development with new approach methodologies
Science · 23.04.2026 · 392 (6796) · 371-378
DOI: 10.1126/science.aeb0045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science, erschienen am 23.04.2026. Verfasst von Xuekun Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Drug Development, Patient-Specific Modeling. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Despite unprecedented technological progress, most drug candidates continue to fail in clinical trials, reflecting a persistent gap between preclinical models and human biology. New approach methodologies (NAMs), by spanning human-derived cellular systems, microphysiological platforms, and artificial intelligence, offer a paradigm shift in human-centric drug development and biomedical research. Recent regulatory reforms, such as the US Food and Drug Administration (FDA) Modernization Act 3.0, have begun to position NAMs as a complement to or replacement for animal testing. This Review synthesizes emerging biological and computational NAMs and examines how their integration is reshaping drug development. We also discuss regulatory and ethical frameworks enabling this transition and outline a roadmap for embedding human-based science in a predictive, efficient, and ethically grounded infrastructure of human-centered drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.
- Greenstone Biosciences, Palo Alto, CA, USA.
- Division of Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health, Bethesda, MD, USA.
ORCID-Profile: Xuekun Wu, Matthew A Wu, James Zou, Nicole Kleinstreuer, Joseph C Wu
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NIA NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Wu, X., Wu, M. A., Zou, J., Kleinstreuer, N., & Wu, J. C. (2026). Reimagining human-centric drug development with new approach methodologies. Science, 392(6796), 371-378. https://doi.org/10.1126/science.aeb0045
Vancouver
Wu X, Wu MA, Zou J, Kleinstreuer N, Wu JC. Reimagining human-centric drug development with new approach methodologies. Science. 2026;392(6796):371-378. doi:10.1126/science.aeb0045
BibTeX
@article{Wu2026,
author = {Wu, Xuekun and Wu, Matthew A and Zou, James and Kleinstreuer, Nicole and Wu, Joseph C},
title = {Reimagining human-centric drug development with new approach methodologies},
journal = {Science},
year = {2026},
volume = {392},
number = {6796},
pages = {371--378},
doi = {10.1126/science.aeb0045}
}
EUVIMED